Gastrointestinal Stromal Tumor

(1) Metastatic or recurrent G-GIST; (2) Concurrent other malignancies; (3) Received neoadjuvant imatinib therapy; (4) Intraoperative conversion to laparotomy...Tumor size >5 cm was an independent risk factor for RFS (P<0.05). Comparing to the laparotomy, laparoscopic operation for G-GISTs had superior perioperative outcomes without compromising oncologic outcomes.

P=N/A, N=136, Recruiting, Chinese University of Hong Kong

P=N/A, N=182, Recruiting, The First Affiliated Hospital with Nanjing Medical University

P2, N=46, Not yet recruiting, Kumquat Biosciences Inc.

For therapeutic categories, performance reached 0.84 for avapritinib sensitivity, 0.81 for imatinib sensitivity. DL applied to WSIs enables prediction of molecular alterations, treatment sensitivity, and RFS in GIST, performing comparably to established risk scores across international cohorts, providing a baseline for future multimodal predictors. Deep learning on histology predicts KIT and PDGFRA mutations in a large international cohort of GISTs from multiple centers Whole-slide image models stratify recurrence-free survival comparable to pathology-based risk scores Prognostic value of deep learning is preserved in adjuvant therapy subgroups, supporting treatment duration decisions.

Targeted tyrosine kinase inhibitors (TKIs) have transformed GIST management, with imatinib as the foundational first-line therapy and subsequent agents, sunitinib, regorafenib, avapritinib, and ripretinib, addressing primary or secondary resistance driven by diverse mutational patterns. Emerging therapeutic directions include next-generation kinase inhibitors, heat shock protein inhibitors, immunotherapy, metabolic and epigenetic targeting, and biomarker-driven individualized treatment strategies. This review synthesizes contemporary advances in the histopathological, molecular, and therapeutic landscape of GISTs, emphasizing an integrated diagnostic approach and highlighting ongoing efforts to overcome therapeutic resistance and optimize personalized care.

This report highlights the importance of timely surgical management of ruptured GISTs, the efficacy of imatinib in both adjuvant and recurrence settings, and the need to consider treatment interruption for reproductive planning. We also review the literature on c-Kit inhibitor therapy in GIST management and discuss emerging evidence on imatinib's effects on fertility, as well as potential strategies for balancing oncological and reproductive goals in young patients with high-risk GIST.

Molecular testing identified a KIT Exon 9 mutation, leading to initiation of imatinib therapy...Multidisciplinary approaches combining imaging, histology, and molecular profiling are essential for optimizing outcomes in these complex cases. This extra-GI/pelvic GIST occurred under chronic posttransplant immunosuppression after renal and liver transplantation; as such, we highlight the transplant-oncology interface, notably, an elevated posttransplant cancer risk, rare but documented GIST after kidney transplant, and TKI-calcineurin-inhibitor interactions that require coordinated management.

P3, N=453, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Trial completion date: Dec 2025 --> Dec 2026

Overexpression as well as loss of MTAP and p16 expression correlated with the presence of epithelioid histology (either pure or mixed with a spindle cell component), higher grade and pT-stage, necrosis, higher NCCN risk groups, and widespread disease at presentation. Overexpression as well as loss of MTAP and p16 expression predicts shortened progression-free survival and is associated with various known poor prognostic clinicopathologic parameters.

Extraluminal cases of IFPs are extremely rare in the literature. Recognising these unusual cases is crucial to prevent misdiagnosis, guide proper surgical management and reassure patients about their prognosis.

This case report presents a highly unusual case of a primary high-grade malignant peripheral nerve sheath tumor (MPNST) of esophagus, a neoplasm of extreme rarity, with fewer than twenty histologically confirmed cases reported worldwide to date; detailing the successful management of this tumor through Orringer's transhiatal esophagectomy, complemented by comprehensive histopathologic and immunohistochemical evaluation. Our report emphasizes the crucial the role of immunohistochemistry, specifically the diagnostic value of S100, SOX10, and the exclusion of gastrointestinal stromal tumors markers (DOG1, CD117) in distinguishing MPNST, from morphologically similar esophageal submucosal tumors.